The Stanford professor was a supporter of herd immunity during the COVID-19 pandemic.
President-elect Donald Trump announced that he has chosen Jay Bhattacharya, MD, PhD, to lead the National Institutes of Health (NIH),1 which is the leading medical research agency in the US. The news represents another major appointment in his administration to tackle health care, after tapping Robert F. Kennedy Jr for the secretary of HHS and Mehmet Oz, MD, to oversee CMS.
Bhattacharya currently works as a professor at Stanford University School of Medicine, identifying both as a physician and a health economist. He has worked formerly with the RAND Corporation and as a research fellow at the Hoover Institution. As leader of the NIH, he would work with Kennedy to direct the research that is conducted in the country.
NIH is a department that falls under HHS and is responsible for funding research on vaccines, cancer, and other diseases through different grants given to research institutions throughout the nation. Thousands of scientists also work with NIH directly to conduct research. All of these responsibilities could be led by Bhattacharya should he be confirmed by the Senate in January.
Bhattacharya is appointed as the nominee for director of the National Institutes of Health | Image credit: Grandbrothers - stock.adobe.com
Bhattacharya has had controversial opinions before this nomination. He was a coauthor of the Great Barrington Declaration that claimed that COVID-19 lockdowns were causing harm to the population in a way that could not be repaired. The paper was released in October 2020, before the first vaccination was available. The authors also called for herd immunity as the solution, with the idea that those at low risk should build immunity to COVID-19 by contracting the virus whereas those at high risk would be protected. The then-NIH director Francis Collins, MD, PhD, was a notable critic of this paper.
The professor from Stanford has also alleged that vaccine mandates that would disallow those unvaccinated from participating in the workplace or other activities undermined trust in the public health system for American citizens. Restrictions on social media have also followed Bhattacharya, who was a plaintiff in a case that alleged that federal officials suppressed conservative views on social media to combat misinformation, a case that he lost.
Alongside the nomination for the leader of NIH, Trump also announced his pick for the deputy secretary of HHS, Jim O’Neill. O’Neill is a former official in HHS, making him the sole nominee thus far with experience in the public health agencies. O’Neill will be in charge of improving management, transparency, and accountability in the HHS, according to Trump’s written statement.
These nominations come a couple weeks after Kennedy was named as Trump's pick for secretary of HHS. With the combination of Bhattacharya’s criticism of vaccine mandates alongside Kennedy’s public skepticism of vaccines,2 the Trump administration is making appointments that could change the way that vaccines are received in the US. Rapid adjustments to the way that vaccines are recommended and delivered would be challenging to enforce due to federal structures and regulatory practices. However, the positions on vaccines from the presumptive nominees could spell challenges to vaccine policy after the second Trump administration is sworn in on January 20, 2025.
References
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More